Navigation Links
PAREXEL Reports First Quarter Fiscal Year 2011 Financial Results
Date:11/1/2010

to assure that the necessary audio applications are downloaded and installed.  A replay of this webcast will be archived on the website approximately two hours after the call and will continue to be accessible for approximately one year following the live event.  To participate via telephone, dial +1 706-758-4950 and ask to join the PAREXEL quarterly conference call.

About the CompanyPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 10,170 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand, such as the guidance provided for the second quarter of Fiscal Year 2011 and Fiscal Year 2011.  For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PAREXEL Consulting Releases Annual Analysis of FDA New Drug Review Trends
2. PAREXEL International to Present at Oppenheimer Healthcare Conference and Morningstar Annual Stocks Forum
3. PAREXEL Opens New Office in Japan and Further Strengthens Leading Presence in Asia/Pacific Region
4. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
5. PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers
6. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
7. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
8. PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference
9. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
10. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
11. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Elekta (NSE:EKTAb) and Royal Philips ... Foundation Trust ( Manchester, UK ), a ... is to develop the clinical value of an integrated ... a system would, in principle, improve the practice of ... "The Christie was an essential participant in the ...
(Date:7/22/2014)... 2014 Sanofi Pasteur, the vaccines division of Sanofi ... that the first lots of Fluzone ® (Influenza Vaccine) ... by the U.S. Food and Drug Administration (FDA) for distribution. ... first of at least 65 million doses of seasonal influenza ... U.S. health care providers and pharmacies in August. ...
(Date:7/22/2014)... SAN DIEGO , July 22, 2014  Halozyme ... that it has resumed enrollment and dosing of patients ... PEGPH20 in patients with pancreatic cancer under the revised ... PEGPH20 is an investigational PEGylated form of Halozyme,s proprietary ... of tumors that accumulate hyaluronan. "Our ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... ALL Study Group Presented Data at the 14th Congress ... in Patients with Minimal Residual Disease , , ... MITI ), a biopharmaceutical company developing novel, proprietary antibodies ... announced that the German Multicenter ALL Study Group (GMALL) ...
... 2 data sets to be released-- , ... clinical trials in patients with blepharospasm and cervical dystonia -- ... -- were presented at the Movement Disorder Society (MDS) 13th ... by Merz Pharmaceuticals, which plans to file a Biologic License ...
Cached Medicine Technology:Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 2Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 3Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 5Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
(Date:7/23/2014)... (PRWEB) July 23, 2014 As the body ... more slowly resulting in old muscle being replaced by fatty ... excess fat in the belly region, the most dangerous area ... fat, actually surrounds the internal organs and circulates through the ... related conditions. , For this reason, Diet Doc’s staff ...
(Date:7/23/2014)... Raleigh, NC (PRWEB) July 23, 2014 ... is chemically similar to the yellow pigment in the ... destroy mesothelioma cells in the lab. To read ... , Scientists at Gazi University in Ankara, Turkey ... with both compounds before exposing them to two platinum-based ...
(Date:7/23/2014)... DC (PRWEB) July 23, 2014 ... some state-run insurance exchanges to come up with ... some of the myriad ways to accomplish this ... Services’s Inside Health Insurance Exchanges (HEX). , “We ... high” for state-run exchanges, Christopher Condeluci, an attorney ...
(Date:7/23/2014)... On July 19 and 20, the HearStrong Foundation ... and New York Giants Health & Fitness Expo 2014 at ... team, which included several hearing healthcare providers affiliated with ... and answered any questions that attendees had about their hearing ... sponsored by the NFL Players Association, HearStrong was proud to ...
(Date:7/23/2014)... Seattle, Wa (PRWEB) July 23, 2014 ... body sweats, it means that it is healthy enough ... is also useful for “washing out” harmful toxins and ... excretory system of the body just cannot do. ... prone to hyperhidrosis—or more commonly known as “excessive sweating”—are ...
Breaking Medicine News(10 mins):Health News:Diet Doc Medical Weight Loss Programs Announces Exclusive Diet Plans for Men that are Simple, Easy to Follow and Melt Dangerous Belly Fat 2Health News:Diet Doc Medical Weight Loss Programs Announces Exclusive Diet Plans for Men that are Simple, Easy to Follow and Melt Dangerous Belly Fat 3Health News:New Research Finds Pretreatment of Mesothelioma Cells with These Two Compounds Boosts Chemotherapy Response, According to Surviving Mesothelioma 2Health News:New Research Finds Pretreatment of Mesothelioma Cells with These Two Compounds Boosts Chemotherapy Response, According to Surviving Mesothelioma 3Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3Health News:The HearStrong Foundation Provides Hearing Healthcare Awareness at the NBC 4 New York and New York Giants Health & Fitness Expo 2014 2Health News:Beat Your Sweating Demons Review | The Problem With Excessive Sweating and Solving it Naturally – Vinamy.com 2Health News:Beat Your Sweating Demons Review | The Problem With Excessive Sweating and Solving it Naturally – Vinamy.com 3
... 18 /PRNewswire-Asia-FirstCall/ -- China YCT International,Group Inc., (OTC ... a,leading company engaged in the business of developing, ... subsidiary, Shandong,Spring Pharmaceutical Co. Ltd, today announced its ... December 31, 2008. , , ...
... Professional Athletes Who Use the OmniPod System to Manage their ... of the country,s top professional cross-country skiers, is competing on ... month. As a world-class athlete, Freeman intends to medal, ... I diabetes. Diabetes doesn,t keep Freeman from performing at ...
... Innovations in the Past 30 Years - Quantros President and Chief ... last week, discussing the importance of using technology to track and ... , ... San Francisco, CA (PRWEB) February 17, 2009 - ...
... International Effort to Combat Rare Diseases That Collectively Effect 1 in 10 ... ... 2009 -- Students at Albany High School in Albany, California, are asking ... support the first annual World Rare Disease Day, an international event being ...
... Growth is expected in Australian pharmaceuticals and ... accounted for 80 percent or $258.6 million and will continue ... same period, life sciences spending on IT accounted for $64.6 ... pharmaceuticals and life sciences market. It is expected to ...
... based Renaissance Laser & Vein Institute eliminates varicose ... OAKS, Calif., Feb. 17 Southern California based ... easy and effective method for eliminating painful and ... proper vein structure is a common problem. ...
Cached Medicine News:Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 2Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 3Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 4Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 5Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 6Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 7Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 8Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 9Health News:Elite Skier Uses OmniPod(R) Insulin Management System at World Championships 2Health News:Quantros President Appears on National TV Promoting Patient Safety 2Health News:Albany High School Students Unite To Raise Awareness and Funds For World Rare Disease Day 2009 2Health News:Albany High School Students Unite To Raise Awareness and Funds For World Rare Disease Day 2009 3Health News:Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing 2Health News:Renaissance Laser & Vein Institute (LaserandVeinclinic.com) Provides Top Notch 'Varicose Vein Treatment' 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: